JAN Janus Living, Inc.
Executive Summary
Janus Living, Inc. (JAN) has priced a 25,000,000 share offering of Class A-1 common stock at $25.00 per share, raising gross proceeds of $625 million (approximately $600.1 million net). The offering price of $25.00 represents a 1.8% discount to the June 2, 2026 close of $25.45. Proceeds will be contributed to the operating company to pursue acquisitions and for general corporate purposes. The offering is sizable relative to existing float but the company has a strong balance sheet with zero debt and $1.5B in liquidity, and the use of proceeds for growth is consistent with the company's stated strategy.
Key Financial Metrics
Actionable Insight
The offering adds ~$600M of dry powder at a modest discount to market. With zero debt and a strong liquidity position, Janus Living is well-positioned to execute its acquisition pipeline (non-binding LOIs for ~$601M and purchase agreements for ~$352M of properties). The large Healthpeak overhang (~65% of Class A-1 shares) limits float and may dampen trading volumes. Monitor for deployment pace and accretive use of proceeds versus simple balance-sheet cash drag.
Key Facts
- 25,000,000 shares offered at $25.00/share (gross proceeds $625M, net ~$600.1M)
- Underwriters have 30-day option for additional 3,750,000 shares (greenshoe, up to $690.3M net)
- Offering price is a 1.8% discount to last closing price of $25.45 on June 2, 2026
- Underwriting discount is $0.9375/share ($23.4M total); underwriters include BofA, J.P. Morgan, RBC, Wells Fargo, Goldman Sachs, Morgan Stanley, Barclays, Jefferies, KeyBanc, TD Securities, and co-managers
- Company had zero debt and $1.5B in liquidity as of March 31, 2026
- Healthpeak (NYSE: DOC) will own ~74.5% of voting power post-offering (~74.0% if greenshoe exercised); this is a controlled company
- Proceeds to be contributed to operating company for acquisitions and general corporate purposes
- Dilution: 25M new shares / ~187.2M existing shares = ~13.4% dilution; ~11.8% if including fully diluted shares
Financial Impact
Gross offering of $625M; net proceeds ~$600.1M (or ~$690.3M with full greenshoe). Dilution of ~13.4% to existing public float (excluding Healthpeak's stake).
Risk Factors
- Dilution of ~13.4% to existing public shareholders
- No committed acquisitions at this time; cash may sit idle
- Significant related-party conflicts: Healthpeak controls both the Manager and ~74.5% voting power
- Concentration of revenue (~80% from two operators, LCS and Sunrise)
- Geographic concentration in Florida and Texas (67% of units), exposed to hurricane risk
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001104659-26-070188 |
| Document: 0001104659-26-070188-index-headers.html | 0001104659-26-070188 |
| Document: 0001104659-26-070188-index.html | 0001104659-26-070188 |
| Document: 0001104659-26-070188.txt | 0001104659-26-070188 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
11d ago
|
424B4
| $24.65 $25.12 | ▲ +1.91% | ▲ +4.48% | $25.73 (+4.38%) |
|
Jun 3, 2026
12d ago
|
EFFECT
| $24.65 $24.65 | · 0.00% | ▼ −0.40% | $25.73 (+4.38%) |
|
Mar 23, 2026
11w ago
|
424B4
| $23.75 $23.75 | · 0.00% | ▲ +0.36% | $25.73 (+8.34%) |
|
Mar 23, 2026
12w ago
|
Insider Cluster
| $23.75 $23.75 | · 0.00% | ▲ +0.36% | $25.73 (+8.34%) |
|
Mar 20, 2026
12w ago
|
EFFECT
| $23.60 $23.75 | ▲ +0.64% | ▼ −0.47% | $25.73 (+9.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access